Episode 2: NASH and Metabolic Syndrome

Overview

In this podcast, AGA Institute’s NASH: Take Action! Steering Committee members talk to global leaders in gastroenterology, hepatology, endocrinology and primary care about the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. In this episode we’re talking about NASH and metabolic syndrome.

Learning Objectives

By the end of this podcast, listeners will be able to:

Describe the relationship between NASH, obesity and associated comorbidities.
Understand the role of obesity, diabetes and insulin resistance in pathogenesis of NAFLD/NASH.
Identify the major risk factors related to the progression from steatosis to steatohepatitis to advanced liver fibrosis/cirrhosis.
Understand the association between CVD and NAFLD and the role of statin therapy.
Increase awareness of the currently available diagnostic and treatment modalities for early intervention and prevention of CVD and cirrhosis.

Key Takeaways

Diabetes, heart disease, and liver disease are strongly interrelated, with adverse cardiovascular outcomes the top cause of death in patients with early-stage fibrosis.
Identifying the subset of patients with obesity at elevated risk of advanced fibrosis, and when to seek help from specialists to prevent cardiovascular complications, is a pressing clinical challenge for primary care providers.
New therapies to address fat deposition in early stages of NAFLD, as well as cardiovascular risk and end-stage complications, are likely within the next decade..

CME

To claim credit, visit AGA University. You will need to create a free account to log in and claim your credit.

This activity is accredited through Sep. 30, 2022.

The AGA Institute is accredited by the ACCME to provide continuing medical education for physicians. The AGA Institute designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Credits

Hosts: Fasiha Kanwal, MD, Baylor College of Medicine; Kenneth Cusi, MD, University of Florida; Jay Shubrook, DO, Touro University

Guest: Lee Kaplan, MD, founding director of the Weight Center at Massachusetts General Hospital

Created by: Knighten Health, LLC

Produced and edited by: Nick Jaworksi

Cover art: THOR Design Studio

‍

Disclosures

Fasiha Kanwal discloses no conflicts.

Kenneth Cusi has received research support for the University of Florida as principal investigator from Cirius, Echosens, Inventiva, Novo Nordisk, Poxel and Zydus and is a consultant for Allergan, Arrowhead, Astra-Zeneca, Axcella, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Fractyl, Hanmi, Genentech, Gilead, HighTide, Inventiva, Intercept, Ionis, Janssen, Pfizer, Poxel, Prosciento, Madrigal, and Novo Nordisk.

Jay H. Shubrook has served as an advisor to Sanofi, Eli Lilly, Novo Nordisk, Bayer, and MannKind.

Lee Kaplan

Sponsor

American Gastroenterological Association

Funding

This podcast series was supported by an independent medical education grant from Novo Nordisk Inc.